Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates

Solventum SOLV reported second-quarter 2026 adjusted earnings per share (EPS) of $2.55, which beat the Zacks Consensus Estimate of $1.91 by 33.5%. The bottom line improved 50.9% year over year.

GAAP EPS in the quarter was 53 cents compared with 51 cents in the year-ago quarter.

SOLV's Sales Gain From Advance Ordering

Revenues of $2.21 billion rose 2.2% and surpassed the consensus mark of $2.17 billion by 2%. Organic sales increased 9.5%, aided by strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.

Following the better-than-expected results, shares of SOLV gained 2.9% in yesterday’s after-market trading. The company’s shares has gained 6.2% in the year-to-date period compared with the industry’s increase of 0.9%. However, the broader S&P 500 Index has increased 12.8% in the same time frame.

Image Source: Zacks Investment Research

Reported growth included a 100-basis-point currency benefit and an 830-basis-point headwind from acquisitions and divestitures. The latter mainly reflected the September 2025 sale of the Purification and Filtration business, partly offset by the Acera acquisition.

Management estimated normalized organic growth of about 4%. This adjusts for roughly 630 basis points of ERP-related advance orders, partly offset by about 100 basis points of SKU rationalization headwinds and a partial separation-timing benefit.

Solventum's MedSurg Business Shows Strength

MedSurg revenues totaled $1.37 billion, up 12.7% on a reported basis and 8.9% organically. ERP advance orders added an estimated 700 basis points to organic growth.

Advanced Wound Care sales rose 14.9% year over year to $537 million, with organic growth of 7.1%. Infection Prevention and Surgical Solutions revenues increased 11.3% year over year to $836 million, while organic sales advanced 10.1% on higher adoption of antimicrobial IV-site management products. Acera contributed $32 million and recorded 48% growth.

SOLV's Dental and HIS Sales Maintain Momentum

Dental Solutions revenues climbed 17% year over year to $396 million, while organic sales rose 15.2%. Advance ordering contributed about 10 percentage points, while new products supported underlying demand in restoratives and aesthetics.

Health Information Systems revenues increased 4.4% year over year to $354 million, with organic growth of 5.4%. Revenue cycle management solutions benefited from healthy customer retention and commercial execution. SOLV also announced its intent to separate Health Information Systems (HIS) to sharpen its MedTech focus and give the software business greater strategic flexibility.

Solventum Q2 Margin Analysis

Adjusted gross profit totaled $1.33 billion, up 9.8% year over year. As a percentage of revenues, the adjusted gross margin expanded 410 basis points to 60.1% from 56% in the prior-year quarter.

Selling, general and administrative expenses totaled $927 million, up 20.1% year over year, mainly due to higher separation-related and net legal costs. Research and development expenses declined 5.8% year over year to $178 million. Adjusted operating expenses totaled $701 million, down 4.8% from the year-ago quarter.

Adjusted operating income increased 32.3% year over year to $627 million. The adjusted operating margin expanded 650 basis points to 28.4%, primarily driven by the tariff refund and ERP-related advance-order timing benefits. Excluding these items, management estimated the adjusted operating margin at approximately 21.7%.

SOLV’s Financial Position

Solventum exited the second quarter with cash, cash equivalents and investments of $403 million compared with $561 million in the previous quarter.

Total assets increased to $14.2 billion from $14.1 billion in the previous quarter.

Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $38 million compared with $198 million in the year-ago period.

Solventum Corporation Price, Consensus and EPS Surprise

Solventum Corporation price-consensus-eps-surprise-chart | Solventum Corporation Quote

Solventum Raises Its 2026 Outlook

Solventum raised the lower end of its 2026 organic sales growth guidance. The company now expects sales to grow by 2.5-3% compared with the earlier guidance of 2-3%. Excluding an expected 100-basis-point SKU exit impact, the company now projects growth of 3.5-4%.

Adjusted earnings guidance increased to $7.10-$7.20 per share from the prior range of $6.40-$6.60. Free cash flow is now expected to be between $200 million and $300 million compared with the earlier estimate of about $200 million.

Our Take

Solventum delivered a strong second-quarter 2026, with earnings and revenues surpassing the Zacks Consensus Estimate. Performance benefited from healthy demand, new product launches and stronger commercial execution across all three segments. MedSurg gained from negative pressure wound therapy and antimicrobial IV-site management products. Dental Solutions benefited from restorative and aesthetics offerings, while HIS maintained momentum in revenue cycle management.

However, the reported growth rate was aided by approximately $125 million of advance orders ahead of ERP cutovers. Management estimated normalized organic growth of about 4% compared with the reported 9.5%. Most of the advance-order benefit is expected to reverse in the third quarter. Adjusted margins also received a sizable lift from a one-time tariff refund. Excluding the refund and ERP timing benefit, the adjusted operating margin was approximately 21.7%. Tariffs and inflation continued to pressure underlying gross profitability.

Solventum continued to advance its transformation and portfolio strategy. The company announced plans to separate the HIS business, which should sharpen its focus on MedSurg and Dental Solutions. Acera remained a bright spot, supported by strong growth and high margins. The company also made progress in winding down its separation from 3M and continued share repurchases. Nonetheless, separation-related spending and legal costs weighed on GAAP profitability and first-half cash generation. The planned HIS transaction also remains at an early stage.

SOLV’s Zacks Rank and Other Key Picks

Solventum currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks from the broader medical space are McKesson MCK, Phibro Animal Health PAHC and Cardinal Health CAH.

McKesson carries a Zacks Rank #2 at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

McKesson shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.

Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.

Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.

Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.

Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research